The study was conducted in July 2010 as a joint project of RosBusinessConsulting and the Maxwell Biotech Group of Companies. The Maxwell Biotech Venture Fund, which is part of the group of the same name, is Russia's first specialized investment fund in the field of medical innovations and biotechnologies.
This study, jointly prepared by the Maxwell Biotech and RosBusinessConsulting analytical groups, opens the direction for studying the most relevant development segments of the Russian and international pharmaceutical market.
Analytical reference is devoted to the description of the market for drugs for the treatment of metastatic renal cell carcinoma (CRP). The study examines the main characteristics of the global market, including development forecasts from various world researchers, an estimate of the market size and number of patients, market structure, global sales of targeted drugs and the annual rate .
Analytical reference includes:
• a description of the factors for the development of CRP and the use of targeted therapy in the global market,
• A description of the global market demand and the potential for the development of the RCC market.
• World market forecast for 2013-2018.
• a comparative analysis of the effectiveness of the main drugs for the treatment of RCC, depending on the stage of the disease.
A full report on the market of medicines for the treatment of CRP in the Russian and world markets can be found here.
The report is supplemented with an English-Russian dictionary of basic terms and abbreviations.
The study was conducted in 2010.
Report Volume 26 pp.
The report contains 8 tables and 5 graphs and charts.
The report language is Russian.
Categories: Consumer Products / Pharmacies / Medicines
Industry / Pharmaceuticals / Medicines
The whole world